MC
RYTM icon

Matisse Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Matisse Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Buy
+4,000
New +$362K 0.18% 106
2020
Q3 		– Sell
-9,130
Closed -$204K – 164
2020
Q2 		$204K Buy
+9,130
New +$178K 0.07% 134

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Matisse Capital's RYTM Position: Q2 2026 in Review

Matisse Capital opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 4,000 shares worth $444K. The stake represents 0.18% of the portfolio and ranks #106 among its holdings. This is a return to the name: Matisse Capital previously reported a position in RYTM as recently as Q2 2020.

Matisse Capital first reported a position in RYTM in Q2 2020 and has held it in 2 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Matisse Capital held 4,000 shares of Rhythm Pharmaceuticals worth $444K as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Matisse Capital position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.18% of Matisse Capital's portfolio in Q2 2026, its #106 holding.
  • Matisse Capital first reported a position in Rhythm Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Matisse Capital's 13F filing for Q2 2026, filed 12 Aug 2026.